Significant changes in blood eosinophils cells, median t0 500 cell/mcl (IQR:340 830), median t6 97 cell/mcl (IQR:60 160) p < 0.001, were greater in patients with AERD. The median baseline VAS score was 6 (IQR:6 7) and the differences between t0 and t6 were statistically significant p < 0.001. A reduction in NPS, median t0 NPS 4 (IQR:4 6), median t6 NPS 1 (IQR:0 1) p < 0.001, was greater in patients with AERD. A statistically significant decrease in the SNOT-22 score was observed (median difference −63 95% CI: −68 −58 p < 0.001) with median t0 76 and IQR (61 90) to t6 10 (5 15). A total of 55 patients were included 49 patients (89%) presented with asthma aspirin exacerbated respiratory disease (AERD) in 28 patients (51%). Nasal endoscopic polyp score (NPS), visual analogue scale (VAS) symptom score, sinonasal outcome test (SNOT-22), asthma control test (ACT) score, fractional exhaled nitric oxide (FeNO), eosinophils blood cells and prednisone intake were assessed at baseline and after 6 months. A single-center retrospective observational study was conducted on severe CRSwNP patients treated with mepolizumab. The aim of this study was to evaluate the efficacy of mepolizumab in patients affected by chronic rhinosinusitis with nasal polyps (CRSwNP) in real-life.

Free download ibm spss statistics 24